Epidemiological Study to Identify Prognosis and Predictive Biomarkers for Advanced or Metastatic Renal Cell Carcinoma

CompletedOBSERVATIONAL
Enrollment

62

Participants

Timeline

Start Date

November 30, 2014

Primary Completion Date

December 31, 2016

Study Completion Date

July 31, 2018

Conditions
Metastatic Renal Cell Carcinoma
Interventions
DRUG

Sunitinib

Identify prognosis and predictive biomarkers of response to sunitinib and pazopanib as first line therapy in avanced or metastatic renal cell carcinoma.

Trial Locations (12)

15706

Hospital Clínico Universitario de Santiago de Compostela, Santiago de Compostela

24080

Hospital Universiario de León, León

28007

Hospital Gregorio Marañón, Madrid

28024

Hospital Universitario Ramón y Cajal, Madrid

28040

Hospital Clínico (Madrid), Madrid

28041

Hospital 12 de Octubre, Madrid

29010

Hospital Universitario Carlos Haya, Málaga

33011

Hospital Universitario central de Asturias, Oviedo

39008

Hospital Marqués de Valdecilla, Santander

50009

Hospital Clínico Lozano Blesa, Zaragoza

09006

Hospital Universitarios de Burgos, Burgos

Unknown

Hospital Universitario La Paz, Madrid

All Listed Sponsors
lead

Spanish Oncology Genito-Urinary Group

OTHER

NCT03519542 - Epidemiological Study to Identify Prognosis and Predictive Biomarkers for Advanced or Metastatic Renal Cell Carcinoma | Biotech Hunter | Biotech Hunter